We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

HORIBA Medical

HORIBA ABX designs, develops and distributes worldwide, in vitro diagnostic systems for biological analysis in medica... read more Featured Products: More products

Download Mobile App





HORIBA Medical Launches HELO and Yumizen G Range

By LabMedica International staff writers
Posted on 05 Feb 2018
HORIBA Medical (Montpellier, France) showcased and launched the HELO island configuration solution and the new Yumizen G Range of coagulation analyzers at MEDLAB Middle East, the world’s largest attended laboratory and IVD exhibition and conference.
 
HORIBA Medical is one of the five segments of the Japanese HORIBA Group and one of the global leaders in the hematology market. More...
At the MEDLAB Middle East 2018 held from February 5-8, 2018 in Dubai, UAE, the company showcased HELO (HORIBA Evolutive Laboratory Organization), an innovative design solution covering all the needs of high throughput automated hematology platforms. The HELO solution is based on four fundamentals pillars: using reference methods to count cells, simplifying the user interface with its solution, consider tube workflow management differently from the competition and purpose a scalable solution to fit laboratory needs. With features such as high throughput of 120 samples per hour, automatic slide maker/stainer, comprehensive automated slide digitalization, automated conveyor with multi possible configurations, hematology middleware and expert validation station, HELO provides the optimum answer to the constant evolution of the laboratory.
 
HORIBA Medical also showcased the new Yumizen G Range of coagulation analyzers, which includes the Yumizen G1550, Yumizen G800, Yumizen G400, Yumizen G200 and Yumizen G100. The Yumizen G100 is the smallest analyzer for point of care laboratories to monitor oral anticoagulant, whereas the Yumizen G1550 is a fully automated, high-capacity coagulation analyzer to manage the diagnostic and monitoring requirements of clinical laboratories with mid to high workload. 
 

Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Online QC Software
Acusera 24•7
New
Repetitive Pipette
VWR® Stepper Pro
New
HPV Molecular Test
BD Onclarity HPV Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Roche’s CE-Marked Elecsys pTau217 blood test is a single‑assay blood test measures phosphorylated tau 217, an indicator of amyloid pathology and a hallmark of Alzheimer’s disease (image credit: Shutterstock)

Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection

Alzheimer’s disease is the most common cause of dementia, yet confirmatory testing remains invasive and hard to access. Diagnosis currently takes an average of 3.5 years, and about 75% of people with dementia... Read more

Molecular Diagnostics

view channel
Image: Clarifying tumor microenvironment features and cancer-cell programs linked to treatment response could provide earlier insight into triple-negative breast cancer therapy (image credit: Shutterstock)

Gene Panel Shows Promise for Predicting Chemotherapy Response in TNBC

Triple-negative breast cancer (TNBC) is an aggressive subtype commonly treated with chemotherapy, yet outcomes vary widely among patients. Understanding the tumor features that drive this variability remains... Read more

Microbiology

view channel
Image: The initiative combines epidemiological and microbiological data with whole-genome sequencing to characterize circulating hospital lineages and resistance determinants (image credit: Shutterstock)

Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals

Antimicrobial resistance (AMR) poses a growing threat to patient safety, with carbapenem-resistant Enterobacterales causing difficult-to-treat infections and leaving clinicians with limited therapeutic options.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.